• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Elutia Inc.

    3/13/25 4:32:59 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    Elutia Inc.

    (Name of Issuer)


    Class A Common Stock

    (Title of Class of Securities)


    05479K106

    (CUSIP Number)


    W. Matthew Zuga
    36 Church Lane,
    Westport, CT, 06880
    (646) 793-3510

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/03/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Capital, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    48,931.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    48,931.00
    11Aggregate amount beneficially owned by each reporting person

    48,931.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    53,818.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    53,818.00
    11Aggregate amount beneficially owned by each reporting person

    53,818.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners QP, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,001,428.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,001,428.00
    11Aggregate amount beneficially owned by each reporting person

    4,001,428.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,813,673.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,813,673.00
    11Aggregate amount beneficially owned by each reporting person

    4,813,673.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    13.2 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners GP, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,813,673.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,813,673.00
    11Aggregate amount beneficially owned by each reporting person

    4,813,673.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    13.2 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Co-Investment Vehicle I, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    499,145.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    499,145.00
    11Aggregate amount beneficially owned by each reporting person

    499,145.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    1.4 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Co-Investment Vehicle II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    259,282.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    259,282.00
    11Aggregate amount beneficially owned by each reporting person

    259,282.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.7 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Capital, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    48,931.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    48,931.00
    11Aggregate amount beneficially owned by each reporting person

    48,931.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.1 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    95,197.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    95,197.00
    11Aggregate amount beneficially owned by each reporting person

    95,197.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.3 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners QP II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,562,431.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,562,431.00
    11Aggregate amount beneficially owned by each reporting person

    4,562,431.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners GP II, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,657,628.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,657,628.00
    11Aggregate amount beneficially owned by each reporting person

    4,657,628.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.8 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    HighCape Partners GP II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,657,628.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,657,628.00
    11Aggregate amount beneficially owned by each reporting person

    4,657,628.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    12.8 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    W. Matthew Zuga
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,520,232.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,520,232.00
    11Aggregate amount beneficially owned by each reporting person

    9,520,232.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    26.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    05479K106


    1 Name of reporting person

    Kevin Rakin
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    90,807.00
    8Shared Voting Power

    9,520,232.00
    9Sole Dispositive Power

    90,807.00
    10Shared Dispositive Power

    9,520,232.00
    11Aggregate amount beneficially owned by each reporting person

    9,611,039.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    26.4 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A Common Stock
    (b)Name of Issuer:

    Elutia Inc.
    (c)Address of Issuer's Principal Executive Offices:

    12510 Prosperity Drive, Suite 370, Silver Spring, MARYLAND , 20904.
    Item 2.Identity and Background
    (a)
    The Schedule 13D is being filed by the following persons (each a "Reporting Person" and collectively, the "Reporting Persons"): HighCape Capital, L.P. HighCape Partners, L.P. HighCape Partners QP, L.P. HighCape Partners GP, LLC HighCape Partners GP, L.P. HighCape Co-Investment Vehicle I, LLC HighCape Co-Investment Vehicle II, LLC HighCape Capital, LLC HighCape Partners II, L.P. HighCape Partners QP II, L.P. HighCape Partners GP II, L.P. HighCape Partners GP II, LLC W. Matthew Zuga Kevin Rakin
    (b)
    The principal business address of the Reporting Persons is 36 Church Lane, Westport, CT 06880.
    (c)
    The Reporting Persons are principally engaged in the business of managing their investments in the securities of the Issuer.
    (d)
    During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws
    (f)
    Each of the Reporting Persons, except for Messrs. Zuga and Rakin, is organized under the laws of the State of Delaware. Each of Messrs. Zuga and Rakin is a citizen of the United States.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented by inserting the following information at the end of Item 4: Purchase Agreement On February 4, 2025 (the "Closing Date"), pursuant to that certain Securities Purchase Agreement, dated February 3, 2025 (the "Purchase Agreement"), by and among HighCape Partners II, L.P., HighCape Partners QP II, L.P., and certain other investors named therein (collectively, the "Investors") and the Issuer, the Investors purchased an aggregate of (i) 5,520,000 shares (the "Shares") of Class A common stock, par value $0.001 per share (the "Class A Common Stock"), of the Company, and (ii) prefunded warrants (the "Prefunded Warrants") to purchase up to an aggregate of 480,000 shares of Class A Common Stock, for total gross proceeds of approximately $15 million. The public offering price for each Share was $2.50. As a result of the Offering, HighCape Partners II, L.P. acquired 8,584 Shares and HighCape Partners QP II, L.P. acquired 411,416 Shares at the public offering price of $2.50 per Share, for a total purchase price of $1.05 million. The foregoing descriptions of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 2 to this Amendment No. 4 and incorporated herein by reference. General The Reporting Persons acquired the securities described in this Amendment No. 4 for investment purposes and intend to review the investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Persons, subject to certain provisions of the law, may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the board of directors, and stockholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Class A Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the board of directors.
    Item 5.Interest in Securities of the Issuer
    (a)
    The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, based on 36,423,482 shares of Class A Common Stock outstanding as of March 3, 2025, as set forth in the Issuer's most recent Form 10-K, filed March 11, 2025. (See table in Exhibit 99.A) Kevin Rakin and W. Matthew Zuga are the managing members of HighCape Partners GP, LLC, which is the general partner of HighCape Partners GP, L.P., which is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. In addition, HighCape Partners GP, L.P. manages each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. Messrs. Rakin and Zuga are the managing members of HighCape Capital, LLC, which is the general partner of HighCape Capital, L.P. Messrs. Rakin and Zuga are also the managing members of HighCape Partners GP II, LLC, which is the general partner of HighCape Partners GP II, L.P., which is the general partner of each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC. Each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held of record by HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP II, LLC and HighCape Partners GP II, L.P. may be deemed to beneficially own the securities held of record by each of HighCape Partners II, L.P., HighCape Partners QP II, L.P. Mr. Rakin may be deemed to beneficially own the securities held of record by the Kevin L. Rakin Irrevocable Trust. Each of the Reporting Persons disclaims beneficial ownership of the securities held by the other Reporting Persons.
    (b)
    See (a) above.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The responses to Items 2, 4 and 5 and Exhibit 2 are hereby incorporated herein.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 2: Form of Securities Purchase Agreement, dated February 3, 2025, by and among Elutia Inc. and the Investors named therein (attached as Exhibit 10.2 to the Form 8-K filed by Elutia, Inc. on February 4, 2025 and incorporated herein by reference (SEC File No. 001-39577)). Exhibit 99.A: Aggregate Number and Percentage of the Class of Securities Identified

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    HighCape Capital, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    HighCape Partners, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Partners QP, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Partners GP, LLC
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    HighCape Partners GP, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    HighCape Co-Investment Vehicle I, LLC
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Co-Investment Vehicle II, LLC
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Capital, LLC
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    HighCape Partners II, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Partners QP II, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP, L.P., its general partner, HighCape Partners GP, LLC, its general partner
    Date:03/13/2025
     
    HighCape Partners GP II, L.P.
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member, HighCape Partners GP II, LLC, its general partner
    Date:03/13/2025
     
    HighCape Partners GP II, LLC
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    W. Matthew Zuga
     
    Signature:/s/ W. Matthew Zuga
    Name/Title:W. Matthew Zuga/Managing Member
    Date:03/13/2025
     
    Kevin Rakin
     
    Signature:/s/ Kevin Rakin
    Name/Title:Kevin Rakin
    Date:03/13/2025
    Get the next $ELUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

      4/A - ELUTIA INC. (0001708527) (Issuer)

      2/20/24 12:27:11 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elutia Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      10/15/24 6:59:31 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/20/24 12:03:03 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Financials

    Live finance-specific insights

    See more
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

      SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

      2/20/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

      Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

      11/14/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

      - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures. Business Highlights: The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro e

      5/8/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

      Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment. Elutia has appointed Dwayne Montgomery as Head of Cardiovascular to lead this newly establish

      5/1/25 4:05:06 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

      SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

      7/31/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ELUT
    SEC Filings

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 30,287 shares and covered exercise/tax liability with 12,413 shares, increasing direct ownership by 7% to 342,378 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/11/25 5:54:33 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Elutia Inc.

      424B5 - ELUTIA INC. (0001708527) (Filer)

      5/8/25 5:12:28 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      5/8/25 4:25:47 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      5/6/25 4:15:59 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care